GlassScriptPhysician profile
Jessie D Te
NPI 1154388932
$7,125.65
in general payments reported to CMS, 2019-2025
37 companies · $600 in 2025
The $600 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,728 · 2020: $1,044 · 2021: $930 · 2022: $1,112 · 2023: $1,019 · 2024: $693 · 2025: $600.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,312.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,311.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $886.04 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $557.32 | 2020-2025 | |
| Amgen INC. | $512.36 | 2019-2025 | Otezla, Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $510.12 | 2019-2024 | Xarelto |
| Abbvie INC. | $459.05 | 2021-2025 | Vraylar, Ubrelvy |
| Sanofi-Aventis U.S. LLC | $427.09 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $417.31 | 2019-2025 | Farxiga, Breztri |
| Lilly USA, LLC | $393.51 | 2019-2024 | Jardiance, Mounjaro, Zepbound |
| Amarin Pharma, INC. | $371.65 | 2019-2022 | |
| Novo Nordisk INC | $350.21 | 2019-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $349.74 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $220.35 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $216.13 | 2019-2023 | Vaxneuvance, Pneumovax 23 |
| Novartis Pharmaceuticals Corporation | $176.96 | 2019-2023 | |
| Allergan, INC. | $173.41 | 2019-2020 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessie Te listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.